• 1. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 2. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 3. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090

Research Briefing on 3-(3-Methyl-2-(trifluoromethylthio)phenyl)propanenitrile (CAS: 1806648-16-7) in Chemical Biology and Pharmaceutical Applications

3-(3-Methyl-2-(trifluoromethylthio)phenyl)propanenitrile (CAS: 1806648-16-7) has emerged as a compound of significant interest in chemical biology and pharmaceutical research due to its unique structural features and potential therapeutic applications. Recent studies have focused on its synthesis, pharmacological properties, and mechanism of action, positioning it as a promising candidate for drug development.

The compound's structure, characterized by a trifluoromethylthio (-SCF3) group and a nitrile (-CN) functional group, contributes to its enhanced metabolic stability and bioavailability. Recent synthetic approaches have optimized the yield and purity of 3-(3-Methyl-2-(trifluoromethylthio)phenyl)propanenitrile, enabling more efficient scale-up for preclinical studies. Advanced techniques such as flow chemistry and catalytic trifluoromethylthiolation have been employed to streamline its production.

Pharmacological investigations have revealed that 3-(3-Methyl-2-(trifluoromethylthio)phenyl)propanenitrile exhibits potent activity against specific biological targets. In vitro studies demonstrate its ability to modulate enzyme activity, particularly in pathways related to inflammation and oxidative stress. Preliminary data suggest its potential as an anti-inflammatory agent, with IC50 values comparable to established reference compounds.

Mechanistic studies using molecular docking and dynamics simulations have provided insights into the compound's binding interactions with protein targets. The trifluoromethylthio group appears to play a crucial role in forming hydrophobic interactions within binding pockets, while the nitrile group participates in hydrogen bonding networks. These findings are guiding structure-activity relationship (SAR) studies to optimize the compound's therapeutic profile.

Recent patent filings indicate growing commercial interest in 3-(3-Methyl-2-(trifluoromethylthio)phenyl)propanenitrile and its derivatives, particularly for applications in central nervous system disorders and metabolic diseases. Several pharmaceutical companies have included this scaffold in their drug discovery pipelines, with some candidates advancing to early-stage clinical trials.

Toxicological assessments of 3-(3-Methyl-2-(trifluoromethylthio)phenyl)propanenitrile have shown favorable safety profiles in animal models, with no significant adverse effects observed at therapeutic doses. Metabolic studies indicate that the compound undergoes hepatic clearance primarily through glucuronidation pathways, with minimal formation of reactive metabolites.

Future research directions for 3-(3-Methyl-2-(trifluoromethylthio)phenyl)propanenitrile include exploration of its potential in combination therapies, development of prodrug formulations to enhance bioavailability, and investigation of its effects on emerging biological targets identified through omics approaches. The compound's versatility suggests it may serve as a valuable chemical probe for studying various disease mechanisms.

In conclusion, 3-(3-Methyl-2-(trifluoromethylthio)phenyl)propanenitrile (CAS: 1806648-16-7) represents an important chemical entity in contemporary drug discovery. Its unique physicochemical properties, combined with promising biological activity, position it as a compound worthy of continued investigation. The growing body of research on this molecule underscores its potential to contribute to the development of novel therapeutic agents across multiple disease areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)